What is the clinical evidence from this study?

Study design: Review. Population: Atherosclerosis. Intervention: Inflammation resolution and lipid-lowering strategies.

What question did this study set out to answer?

To review preclinical and clinical advances in atherosclerosis resolution, focusing on inflammation-resolving pathways and structural plaque remodeling beyond standard cholesterol reduction.

August 15, 2026Current Opinion in Lipidology

Atherosclerosis resolution: strategies to remodel and resolve plaques

View Full Paper

Ask AI

Bookmark

Key result

Dual lipid-lowering and anti-inflammatory therapy drives substantial atherosclerotic plaque resolution in preclinical models.

Population

Patients with residual cardiovascular risk despite cholesterol lowering, and preclinical models of…

Design

Review

Authors

EHEmily HalbedlSarnoff Cardiovascular Research Foundation EFEdward A. Fisher

Discussion

Member takes

Implication

This review emphasizes that targeting inflammation alongside lipid-lowering is a promising therapeutic strategy for remodeling atherosclerotic plaques and reducing residual cardiovascular risk.

Key Points

To review preclinical and clinical advances in atherosclerosis resolution, focusing on inflammation-resolving pathways and structural plaque remodeling beyond standard cholesterol reduction.
Synthesized preclinical and translational evidence on plaque resolution mechanisms, including efferocytosis, pro-resolving macrophages, platelet dynamics, and caloric restriction.
Evaluated clinical trial data examining therapeutic targets across inflammatory pathways, including interleukin-1β, interleukin-6, NLRP3, and specialized pro-resolving mediators.
Preclinical studies demonstrate that effective plaque resolution primarily involves qualitative remodeling—such as reduced necrotic core size, decreased CD68 macrophage area, and increased collagen content—rather than simple plaque size reduction.
Combination strategies that pair lipid-lowering therapies with targeted inflammation resolution yield superior plaque stabilization and risk reduction compared to single-modality approaches.

Structured PICO

Population

Patients with residual cardiovascular risk despite cholesterol lowering, and preclinical models of atherosclerosis

Intervention

Lipid-lowering strategies and inflammation-targeting therapies (including IL-1β, IL-6, NLRP3, and pro-resolving mediators)

Outcome

Atherosclerosis resolution and plaque remodeling (measured by necrotic core, CD68 area, and collagen content)

This review emphasizes that targeting inflammation alongside lipid-lowering is a promising therapeutic strategy for remodeling atherosclerotic plaques and reducing residual cardiovascular risk.

Cite This Study

Halbedl et al. (2026) conducted a review in Atherosclerosis. Inflammation resolution and lipid-lowering strategies was evaluated. Targeting inflammatory pathways alongside lipid-lowering promotes significant atherosclerotic plaque remodeling and resolution in preclinical models and is being evaluated in clinical trials.

synapsesocial.com/papers/6a801a3a75c2e31742c86dcc https://doi.org/10.1097/mol.0000000000001050

View Full Paper

Ask AI

Bookmark

Implication

This review emphasizes that targeting inflammation alongside lipid-lowering is a promising therapeutic strategy for remodeling atherosclerotic plaques and reducing residual cardiovascular risk.

Atherosclerosis resolution: strategies to remodel and resolve plaques

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Atherosclerosis resolution: strategies to remodel and resolve plaques

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider